Tranexamic acid (TXA) is a popular antifibrinolytic drug widely used in hemorrhagic trauma
patients and cardiovascular, orthopedic, and gynecological surgical patients. TXA binds …

Hemorrhagic shock (HS) management is based on a timely, rapid, definitive source control
of bleeding/s and on blood loss replacement. Stopping the hemorrhage from progressing …

Trauma-induced bleeding is a leading cause of preventable mortality worldwide. 1–3
Severely injured bleeding trauma patients frequently present with trauma-induced …

Hemorrhage is the leading cause of trauma-related deaths, in hospital and prehospital
settings. Hemostasis is a complex mechanism that involves a cascade of clotting factors and …

Background/Aims There are increasing pressures for anonymised datasets from clinical
trials to be shared across the scientific community, and differing recommendations exist on …

Introduction Hemorrhage in major trauma is life-threatening and the activation of the
Massive Transfusion Protocol (MTP) was found to reduce the time to transfusion and …

Rapid assessment of the fibrinolytic status in whole blood at the point-of-care/point-of-injury
(POC/POI) is clinically important to guide timely management of uncontrolled bleeding in …

Objective Trauma is the leading cause of childhood death in the United States. Our goal was
to determine the effectiveness of tranexamic acid (TXA) in improving survival in pediatric …

Introduction Perioperative bleeding poses a major risk during liver surgery, which can result
in increased transfusion requirements, morbidity, and mortality. Tranexamic acid (TXA) …

Background Tranexamic acid (TXA) has shown to significantly reduce perioperative blood
loss in elective orthopedic joint replacement surgery but is yet not implemented in acute hip …